ACT Share Price

Open 258.10 Change Price %
High 258.55 1 Day -7.55 -2.85
Low 257.25 1 Week -7.90 -2.98
Close 257.45 1 Month 1.75 0.68
Volume 391 1 Year 115.15 80.92
52 Week High 266.90
52 Week Low 125.25
ACT Important Levels
Resistance 2 258.66
Resistance 1 258.16
Pivot 257.75
Support 1 256.74
Support 2 256.24
ETR Germany Most Active Stocks
CBK 9.10 9.38%
CBK 9.10 9.38%
DBK 16.99 9.19%
DBK 16.99 9.19%
EOAN 7.26 1.26%
EOAN 7.26 1.26%
DTE 16.36 2.70%
DTE 16.36 2.70%
DTE 16.36 2.70%
DTE 16.36 2.70%
More..
ETR Germany Top Gainers Stocks
ARO 0.02 100.00%
ARO 0.02 100.00%
S9H 0.16 45.45%
TLI 0.17 21.43%
TLI 0.17 21.43%
E8X 0.80 14.29%
5M71 39.00 13.70%
A8A 6.85 13.04%
ZSB 0.10 11.11%
SGE 50.70 9.86%
More..
ETR Germany Top Losers Stocks
MPI 0.25 -98.98%
MPI 0.25 -98.98%
APL 2.60 -34.18%
APL 2.60 -34.18%
APL 2.60 -34.18%
2GB 21.70 -8.82%
CR8 8.15 -8.53%
EDGA 3.35 -8.22%
EDG 3.36 -7.44%
EDG 3.36 -7.44%
More..

Actelion Ltd (ETR: ACT)

ACT Technical Analysis 4
As on 24th Apr 2017 ACT Share Price closed @ 257.45 and we RECOMMEND Strong Buy for LONG-TERM with Stoploss of 184.84 & Buy for SHORT-TERM with Stoploss of 256.63 we also expect STOCK to react on Following IMPORTANT LEVELS.
ACT Target for April
1st Target up-side 269.64
2nd Target up-side 273.59
3rd Target up-side 277.55
1st Target down-side 258.36
2nd Target down-side 254.41
3rd Target down-side 250.45
ACT Other Details
Segment EQ
Market Capital 0.00
Sector Healthcare
Industry Biotechnology
Offical website http://www.actelion.com
ACT Address
ACT
Gewerberstrasse 16
Allschwil, 4123
Switzerland
Phone: 41 61 565 65 65
Fax: 41 61 565 65 00
ACT Latest News
Interactive Technical Analysis Chart Actelion Ltd ( ACT ETR Germany )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Actelion Ltd
ACT Business Profile
Actelion Ltd, a biopharmaceutical company, discovers, develops, and commercializes drugs for diseases with unmet medical needs. Its products include Tracleer, a dual endothelin receptor antagonist for the treatment of pulmonary arterial hypertension (PAH), a chronic and life-threatening disorder that severely compromises the functions of the lungs and heart; Opsumit, an orally available endothelin receptor antagonist; and Valchlor, a chemotherapeutic agent for the treatment of mycosis fungoides, a common type of cutaneous T-cell lymphoma. The company also provides Veletri, a formulation of epoprostenol for the treatment of PAH; Ventavis, an inhaled formulation of iloprost for the treatment of PAH; and Zavesca, an oral treatment for patients with mild to moderate type 1 Gaucher disease for whom enzyme replacement therapy is unsuitable. Actelion Ltd markets its products in Switzerland, the United States, Japan, China, Russia, and Mexico. The company was founded in 1997 and is headquartered in Allschwil, Switzerland.